Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: Is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?

Blood

Volumn 119, Issue 14, 2012, Pages 3219-3225

  Hasselbalch, Hans Carl ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ATHEROSCLEROSIS; AUTOIMMUNITY; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CLONAL EVOLUTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; GLOMERULOPATHY; HUMAN; HYPERURICEMIA; INSULIN RESISTANCE; MONOCYTE; MORBIDITY; MYELOFIBROSIS; MYELOPROLIFERATIVE GLOMERULOPATHY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SECOND CANCER; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84859584516     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-394775     Document Type: Review

References (100)

1. Campbell PJ, Green AR. Mechanisms of disease: the myeloproliferative disorders. N Engl J Med. 2006;355(23):2452-2466.
2. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH, IKZF1. Leukemia. 2010;24(6):1128-1138.
3. Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011; 96(2):315-318.
4. Hasselbalch H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol. 1990;34(4): 291-300. (Pubitemid 20223505)
5. Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95(7):1216-1220.
6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
7. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3): 204-212.
8. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol. 2006;2(2):99-106. (Pubitemid 43239209)
9. Rho YH, Chung CP, Oeser A, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2009; 61(11):1580-1585.
10. Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol. 2009;161(1):1-7.
11. Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med. 2003; 349(25):2379-2380. (Pubitemid 37542984)
12. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004; 25(1):4-7. (Pubitemid 38032801)
13. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94(9):3171-3182.
14. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348(15):1435-1441. (Pubitemid 36407172)
15. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448-454. (Pubitemid 29084777)
16. Bisoendial RJ, Kastelein JJ, Stroes ES. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis. 2007;195(2):e10-e18. (Pubitemid 350087968)
17. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006;113(17):2135-2150.
18. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-140.
19. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354(6):610-621. (Pubitemid 43209108)
20. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482-2494.
21. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol. 2010;30(12):2357-2361.
22. Lindahl B, Toss H, Siegbahn A, Venge P,Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med. 2000;343(16): 1139-1147.
23. Peri G, Introna M, Corradi D, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102(6):636-641. (Pubitemid 30640663)
24. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275-290. (Pubitemid 40216149)
25. Landolfi R, Di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms. Haematologica. 2011;96(2):183-186.
26. Di Nisio M, Barbui T, Di Gennaro L, et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136(2):249-259. (Pubitemid 46020752)
27. Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol. 2007;35(5):702-711. (Pubitemid 46601748)
28. Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009;114(4):759-763.
29. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117(22):5857-5859.
30. Quist-Paulsen P, Naess IA, Cannegieter SC, et al. Arterial cardiovascular risk factors and venous thrombosis: results from a populationbased, prospective study (the HUNT 2). Haematologica. 2010;95(1):119-125.
31. Norata GD, Marchesi P, Pulakazhi Venu VK, et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation. 2009;120(8):699-708.
32. Pamuk ON, Unlü E, Cakir N. Role of insulin resistance in increased frequency of atherosclerosis detected by carotid ultrasonography in rheumatoid arthritis. J Rheumatol. 2006;33(12):2447-2452. (Pubitemid 46067824)
33. La Montagna G, Cacciapuoti F, Buono R, et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res. 2007;4(2):130-135. (Pubitemid 47167497)
34. Kato M, Hisatome I, Tomikura Y, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol. 2005;96(11): 1576-1578. (Pubitemid 41690182)
35. Tomiyama H, Higashi Y, Takase B, et al. Relationships among hyperuricemia, metabolic syndrome, and endothelial function. Am J Hypertens. 2011;24(7):770-774.
36. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388-1393.
37. Said SM, Leung N, Sethi S, et al. Myeloproliferative neoplasms cause glomerulopathy. Kidney Int. 2011;80(7):753-759.
38. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-867. (Pubitemid 36019639)
39. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(11):2373-2380. (Pubitemid 350022405)
40. Mantovani A, Garlanda C, Allavena P. Molecular pathways and targets in cancer-related inflammation. Ann Med. 2010;42(3):161-170.
41. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-545. (Pubitemid 32173595)
42. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749-759. (Pubitemid 41400849)
43. Martin DN, Mikhail IS, Landgren O. Autoimmunity and hematologic malignancies: associations and mechanisms. Leuk Lymphoma. 2009;50(4):541-550.
44. Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas: an update. J Intern Med. 2008;264(6):514-527.
45. van de Schans SA, van Spronsen DJ, Hooijkaas H, Janssen-Heijnen ML, Coebergh JW. Excess of autoimmune and chronic inflammatory disorders in patients with lymphoma compared with all cancer patients: a cancer registry-based analysis in the south of the Netherlands. Autoimmun Rev. 2011;10(4):228-234.
46. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100(5):822-828.
47. Kristinsson SY, Björkholm M, Hultcrantz M, Derolf ÅR, Landgren O, Goldin LR. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol. 2011;29(21):2897-2903.
48. Panteli KE, Hatzimichael EC, Bouranta PK, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005; 130(5):709-715. (Pubitemid 43906643)
49. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011; 29(10):1356-1363.
50. Skov V, Larsen TS, Thomassen M, et al. Whole blood transcriptional profiling of interferoninducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol. 2011;87(1):54-60.
51. Skov V, Larsen TS, Thomassen M, et al. Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116:4115.
52. Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2068-2073.
53. Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sørensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118(25):6515-6520.
54. Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG. Myelodysplasia- associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest. 2004;34(10):690-700. (Pubitemid 39423027)
55. Rondeau E, Solal-Celigny P, Dhermy D, et al. Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis. Br J Haematol. 1983; 53(3):467-475. (Pubitemid 13153265)
56. Hasselbalch H, Nielsen H, Berild D, Kappelgaard E. Circulating immune complexes in myelofibrosis. Scand J Haematol. 1985;34(2):177-180. (Pubitemid 15158499)
57. Rizzi R, Pastore D, Liso A, et al. Autoimmune myelofibrosis: report of three cases and review of the literature. Leuk Lymphoma. 2004;45(3):561-566. (Pubitemid 38196040)
58. Barosi G, Magrini U, Gale RP. Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis? Leuk Res. 2010;34(9):1119-1120.
59. Hermouet S, Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defence against infection? Haematologica. 2011;96(11):1575-1579.
60. Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE. The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica. 2011;96(3):450-453.
61. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood. 2006;107(12):4589-4596. (Pubitemid 43882602)
62. Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther. 2007;7(4):449-460. (Pubitemid 46524672)
63. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010;31(6):220-227.
64. Fleischman AG, Aichberger KJ, Luty SB, et al. Tumor necrosis factor-alpha facilitates clonal expansion of JAK2V617F-positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392-6398.
65. Barrett JC, Hansoul S, Nicolae DL, et al. Genomewide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40(8):955-962.
66. Ferguson LR, Han DY, Fraser AG, et al. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res. 2010; 690(1):108-115.
67. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2008;111(5):2785-2789.
68. Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)- positive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455-459.
69. Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009; 41(4):446-449.
70. Olcaydu D, Harutyunyan A, Jäger R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009; 41(4):450-454.
71. Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010;24(1):105-109.
72. Jones AV, Campbell PJ, Beer PA, et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010;115(22): 4517-4523.
73. Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood. 2008; 112(4):1402-1412.
74. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70. (Pubitemid 30046295)
75. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002;2(10):725-734.
76. Beg AA, Baltimore D. An essential role for NFkappaB in preventing TNF-alpha induced cell death. Science. 1996;274(5288):782-784. (Pubitemid 26398258)
77. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammationassociated cancer. Nature. 2004;431(7007):461-466. (Pubitemid 39329586)
78. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002; 13(2):135-141. (Pubitemid 34229388)
79. Pittet MJ, Swirski FK. Monocytes link atherosclerosis and cancer. Eur J Immunol. 2011;41(9): 2519-2522.
80. Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31(11):1503-1509. (Pubitemid 47632786)
81. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39-51.
82. Mantovani A, Germano G, Marchesi F, Locatelli M, Biswas SK. Cancer-promoting tumor-associated macrophages: new vistas and open questions. Eur J Immunol. 2011;41(9):2522-2525.
83. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005; 23(10):2224-2232. (Pubitemid 46218714)
84. Monaco C, Andreakos E, Kiriakidis S, et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci U S A. 2004;101(15): 5634-5649.
85. Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010;55(19):2049-2061.
86. Lieb W, Gona P, Larson MG, et al. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular diseases and mortality. Arterioscler Thromb Vasc Biol. 2010;30(9):1849-1854.
87. Rameshwar P, Denny TN, Stein D, Gascón P. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines: potential role for interleukin-1 and TGF-beta. J Immunol. 1994;153(6):2819-2830. (Pubitemid 24278151)
88. Rameshwar P, Chang VT, Thacker UF, Gascón P. Systemic transforming growth factor-beta in patients with bone marrow fibrosis: pathophysiological implications. Am J Hematol. 1998;59(2):133-142. (Pubitemid 28443240)
89. Komura E, Tonetti C, Penard-Lacronique V, et al. Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res. 2005;65(8):3281-3289. (Pubitemid 40524612)
90. Oku S, Takenaka K, Kuriyama T, et al. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation. Br J Haematol. 2010;150(3):334-344.
91. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.
92. Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol. 2005;25(4): 658-670. (Pubitemid 40463851)
93. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179-3184.
94. Verstovsek S, Kantarjian H, Mesa RA, et al. A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
95. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446-455.
96. Andersen CL, Ejerblad E, Zweegman S, et al. A Phase II study of vorinostat (MK-0683) in patients with polycythaemia vera essential thrombocythaemia [abstract]. Haematologica. 2011;16th Congress of The European Hematology Association: Abstract 1032.
97. Hasselbalch HC, Riley CH. Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res. 2006;30(10):1217-1225. (Pubitemid 44223726)
98. Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. A mechanistic rationale for the use of statins to enhance JAK2 inhibitor therapy in MPNs [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118: Abstract 2816.
99. Hasselbalch HC. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer: time to change our therapeutic attitude with early upfront treatment? Leuk Res. 2009;33(1):11-18.
100. Hasselbalch HC. A new era for interferon-alpha2 in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol. 2011;4(6):637-655.